Aberrant expression of cell cycle regulatory genes predicts overall and disease free survival in malignant pleural mesothelioma patients

Experimental and Molecular Pathology

Volumn 93, Issue 1, 2012, Pages 154-161

  Bahnassy, Abeer A ^a   Zekri, Abdel Rahman N ^b   Abou Bakr, Amany A ^a   El Deftar, Mervat M ^a   El Bastawisy, Ahmad ^b   Sakr, Mona A ^a   El sherif, Ghada M ^b   Gaafar, Rabab M ^b  

^a NATIONAL CANCER INSTITUTE   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Malignant pleural mesothelioma; P14; P16; P21 WAF; P27; P53; Prognosis; Rb

Indexed keywords

ASBESTOS; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; PLATINUM; PROTEIN MDM2; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER TISSUE; CARCINOGENESIS; CELL CYCLE REGULATORY GENE; CHEMORADIOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EGYPT; EXPOSURE; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MDM2 GENE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; P14 ARF GENE; P16 INK4A GENE; P21 WAF GENE; P27 KIP GENE; P53 GENE; PLEURA MESOTHELIOMA; POLYMERASE CHAIN REACTION; POLYOMAVIRUS INFECTION; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RB GENE; REGULATOR GENE; SIMIAN VIRUS 40;

ADULT; AGED; CELL CYCLE; CELL CYCLE PROTEINS; DISEASE-FREE SURVIVAL; EGYPT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; YOUNG ADULT;

EID: 84861000494     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2012.04.001     Document Type: Article

References (38)

1. Baldi A., Groeger A.M., Esposito V., Cassandro R., Tonini G., Battista T., et al. Expression of p21WAF in SV40 large T antigen positive human pleural mesothelioma: relationship with survival. Thorax 2002, 57:353-356.
2. Baldi A., Santini D., Vasaturo F., Santini M., Vicidomini G., Marino M., et al. Prognostic Significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21WAF and p27 in human pleural malignant mesothelioma. Thorax 2004, 59:428-433.
3. Beer T.W., Shepherd P., Pullinger N.C. p27 immunostaining is related to prognosis in malignant mesothelioma. Histopathology 2001, 38:535-541.
4. kip1 immunoreactivity correlates with long-term survival in pleural malignant mesothelioma. Cancer 2001, 92:1245-1250.
5. Carbone M., Kratzke R., Testa J. The pathogenesis of mesothelioma. Seminars in Oncology 2002, 29:2-17.
6. Cheng J.Q., Jhanwar S.C., Lu Y.Y., Testa J.R. Homozygous deletions within 9p21-p22 identify a small critical region of chromosomal loss in human malignant mesotheliomas. Cancer Research 1993, 53:4761-4763.
7. Chiosea S., Krasinskas A., Cagle P.T., Mitchell K.A., Zander D.S., Dacic S. Diagnostic importance of 9p21WAF homozygous deletion in malignant mesotheliomas. Modern Pathology 2008, 21(6):742-747.
8. Churg A., Roggli V., Gallateau-Salle F., et al. Mesothelioma. World Health Organization Classification of Tumors Pathology and Genetics: Tumors of the Lung, Pleura, Thymus and Heart 2004, 128-136. IARC Press, Lyon, France. W.D. Travis, E. Brambilla, H.K. Muller-Hermelink, C.C. Harris (Eds.).
9. Creaney J., McLaren B.M., Stevenson S., Musk A.W., de Klerk N., Robinson B.W., et al. p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression. British Journal of Cancer 2001, 84:52-56.
10. Crispi S., Cardillo I., Spugnini E.P., Citro G., Menegozzo S., Baldi A. Biological agents involved in malignant mesothelioma: relevance as biomarkers or therapeutic targets. Current Cancer Drug Targets 2010, 10(1):19-26. Feb 1.
11. Curran D., Sahmoud T., Therasse P., van Meerbeeck J., Postmus P.E., Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. Journal of Clinical Oncology 1998, 16:145-152.
12. INK4a peptide. Anticancer Research 2008, 28:1-8.
13. Giannoudis A., Herrington C.S. Differential expression of p53 and p21WAF in low grade cervical squamous intraepithelial lesions infected with low, intermediate, and high risk human papillomavirus. Cancer 2000, 15:1300-1307.
14. Herndon J., Green M., Chahinian A., Corson J., Suzuki Y., Vogelzang N. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998, 113:723-731.
15. Hirao T., Bueno R., Chen C.J., Gordon G.J., Heilig E., Kelsey K.T. Alterations of the p16(INK4) locus in human malignant mesothelial tumors. Carcinogenesis 2002, 23:1127-1130.
16. Illei P.B., Rusch V.W., Zakowski M.F., Ladanyi M. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clinical Cancer Research 2003, 9:2108-2113.
17. Isik R., Metintas M., Gibbs A.R., Metintas S., Jasani B., Oner U., et al. p53, p21WAF and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure. Respiratory Medicine 2001, 95:588-593.
18. Khaled H.M., Bahnassy A.A., Raafat A.A., Zekri A.R., Madboul M.S., Mokhtar N.M. Clinical significance of altered nm23-H1, EGFR, RB and p53 expression in bilharzial bladder cancer. BMC Cancer 2009, 9:32. Jan 26.
19. Kobayashia N., Toyookaa S., Yanaib H., Soha J., Fujimotoc N., Yamamotoa H., et al. Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma. Lung Cancer 2008, 62:120-125.
20. INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. Journal of the National Cancer Institute 1995, 87:1870-1875.
21. Kumar P., Kratzke R. Molecular prognostic markers in malignant mesothelioma. Lung Cancer 2005, 49S1:S53-S60.
22. Lopez-Rios F., Chuai S., Flores R., et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray based prognostic prediction. Cancer Research 2006, 66:2970-2979.
23. Masumoto T., Fuji T., Ishikawa M., Saito M., Iwata T., Fukuchi T., et al. p16 overexpression and human papillomavirus infection in small cell carcinoma of the uterine cervix. Human Pathology 2003, 34:778-783.
24. Mattar R., Nonogaki S., Silva C., Alves V., Gama-Rodrigues J.J. P53 and Rb tumor suppressor gene alterations in gastric cancer. Revista do Hospital das Clínicas 2004, 59:172-180.
25. INK4a genes in primary central nervous system lymphomas. Cancer Research 2001, 16:6335-6339.
26. Niehans G., Kratzke R., Froberg M., Aeppli D., Nguyen P., Geradts J. G1 checkpoint protein and p53 abnormalities occur in most invasive transitional cell carcinomas of the urinary bladder. British Journal of Cancer 1999, 80:1175-1184.
27. Ordonez N.G. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesothelioma and serous carcinomas: a comparative study. Modern Pathology 2006, 19:34-48.
28. Papp T., Schipper H., Pemsel H., Bastrop R., Muller K.M., Wiethege T., et al. Mutational analysis of N-ras, p53, p16INK4a, p14ARF and CDK4 genes in primary human malignant mesotheliomas. International Journal of Oncology 2001, 18:425-433.
29. Røe O.D., Anderssen E., Helge E., Pettersen C.H., Olsen K.S., Sandeck H., Haaverstad R., Lundgren S., Larsson E. Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype. PLoS One 2009, 4(8):e6554.
30. Sherr C.J. Cancer cell cycles. Science 1996, 274:1672-1677.
31. Steeg P., Abrams J. Cancer prognostics: past, present and p27. Nature Med 1997, 3:152-154.
32. Takeda M., Kasai T., Enomoto Y., Takano M., Morita K., Kadota E., Nonomura A. 9p21WAF deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis. Pathology International 2010, 60(5):395-399. May.
33. Van Ruth S., Baas P., Zoetmulder F.A. Surgical treatment of malignant mesothelioma: a review. Chest 2003, 123:551-561.
34. Waheed I., Guo Z., Chen G., Weiser T., Nguyen D., Schrump D. Antisense to SV40 early gene region induces growth arrest and apoptosis in T-antigen-positive human pleural mesothelioma cells. Cancer Research 1999, 59:6068-6073.
35. INK4a expression in malignant mesothelioma by methylation. Lung Cancer 2002, 38:131-136.
36. Yang C.T., You L., Yeh C.C., Chang J.W., Zhang F., McCormick F., et al. Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells. Journal of the National Cancer Institute 2000, 92:636-641.
37. Zandecki M., Facon T., Preudhomme C., Vanrumbeke M., Vachee A., Quesnel B., Lai J.L., Cosson A., Fenaux P. The retinoblastoma gene (RB-1) status in multiple myeloma: a report on 35 cases. Leukemia & Lymphoma 1995, 18(5-6):497-503.
38. Zekri A.-R.N., Bahnassy A., Mohamed W.S., Hassan N.A., Abdel-Rahman M.A., Abou-El-Kasem F., Gaafar R.M. Evaluation of siamian virus as a biological prognostic factor in Egyptian patients with malignant pleural mesothelioma. Pathology International 2007, 57:493-501.